Research into: Tirosine Kinase Inhibitors (TKI) Used in the Treatment of Non-Small Cell Lung Cancer (NSCLC) Based on Specific Genetic Alterations

Author(s) Details:

Alexandru Calin Grigorescu
Compartment of Medical Oncology, Clinical Hospital for Nephrology “Dr Carol Davila”, Calea Grivitei Nr4, Bucharest, Romania

This section is a part of the chapter: Tirosine Kinase Inhibitors (TKI) Used in the Treatment of Non-Small Cell Lung Cancer (NSCLC) Based on Specific Genetic Alterations

Lung cancer is the leading cause of cancer deaths worldwide. Lung cancer causes more deaths than blood, colorectal, prostate, and brain cancers combined. In 2021, an estimated 235,760 new cases of lung cancer were diagnosed in the United States. The number of deaths was estimated at over 131,880. Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for more than two-thirds of cases. Most patients (84%) have advanced disease at the time of diagnosis.

How to Cite

Nasrat, A. M., Nasrat, S. A., Nasrat, R. M., Nasrat, M. M., & Babiker, S. Y. (2025). Helicobacter pylori and Hyperuricemia: Revisiting Gout Diagnosis in Young Adults with Normal Renal Function. Medical Science: Trends and Innovations Vol. 4, 1–8. https://doi.org/10.9734/bpi/msti/v4/3641

To Read the Complete Chapter See Here

Leave a Reply

Your email address will not be published. Required fields are marked *